If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
The Earl S. Richardson Library's is the main academic information resource center on the campus. Constructed in 2008, the building covers approximately 222,517 square feet. The library's holding constitutes over 500,000 volumes, and access to over 1 million e-books and 5,000 periodical titles. There are 167 online databases that are subscribed to the Library. Reading and studying spaces are provided with wired and wireless access to databases for research. One such collection in the volumes includes books on Africa, with an emphasis on sub-Saharan Africa. The African-American collection includes papers and memorabilia of such persons as Emmett Jay Scott, secretary to Booker T. Washington. The Forbush Collection is composed of materials associated with the Quakers and slavery. The Martin D. Jenkins Collection was acquired in 1980.
== Ion gating == A Bradbury–Nielsen shutter is a type of ion gate used in TOF mass spectrometers and in ion mobility spectrometers, as well as Hadamard transform TOF mass spectrometers. The Bradbury–Nielsen shutter is ideal for fast timed ion selector (TIS)—a device used for isolating ions over narrow mass range in tandem (TOF/TOF) MALDI mass spectrometers.
=== Rise of the galactic city === The term "galactic city", associated with Lewis Mumford, describes a dispersed form of metropolitan development. Twentieth-century urban growth in parts of the United States was supported by several infrastructure and technological changes, including highway transportation, air conditioning, expanded agricultural production and systems for transporting and storing food over long distances. Refrigeration contributed to this broader infrastructure by allowing urban populations to obtain perishable food from distant agricultural regions rather than depending primarily on nearby production. In analyses of settlement patterns, refrigeration has therefore been identified as one of several technologies that reduced constraints on population growth in locations distant from traditional agricultural and transport centres.
Similarly, accumbal G9a hyperexpression results in markedly increased histone 3 lysine residue 9 dimethylation (H3K9me2) and blocks the induction of ΔFosB-mediated neural and behavioral plasticity by chronic drug use, which occurs via H3K9me2-mediated repression of transcription factors for ΔFosB and H3K9me2-mediated repression of various ΔFosB transcriptional targets (e.g., CDK5). ΔFosB also plays an important role in regulating behavioral responses to natural rewards, such as palatable food, sex, and exercise. Since both natural rewards and addictive drugs induce the expression of ΔFosB (i.e., they cause the brain to produce more of it), chronic acquisition of these rewards can result in a similar pathological state of addiction. Consequently, ΔFosB is the most significant factor involved in both amphetamine addiction and amphetamine-induced sexual addictions, which are compulsive sexual behaviors that result from excessive sexual activity and amphetamine use. These sexual addictions are associated with a dopamine dysregulation syndrome which occurs in some patients taking dopaminergic drugs. The effects of amphetamine on gene regulation are both dose- and route-dependent. Most of the research on gene regulation and addiction is based upon animal studies with intravenous amphetamine administration at very high doses. The few studies that have used equivalent (weight-adjusted) human therapeutic doses and oral administration show that these changes, if they occur, are relatively minor.
Sources: en.wikipedia.org
== In popular culture == George Sessions Perry's 1941 novel Hold Autumn in Your Hand – and Jean Renoir's 1945 film adaptation of it, The Southerner – incorporates pellagra ("spring sickness") as a major plot element in the story of an impoverished Texas farm family. Satirical singer/pianist Tom Lehrer referred to pellagra as an endemic disease of the Southern states in the lyrics of his 1960 song "I Wanna Go Back to Dixie" -- "I'll go back to the Swanee / Where pellagra makes ya scrawny / And the honeysuckle clutters up the vine." Season 2, Episode 22 of House, titled "Forever", focuses on a new mother diagnosed with pellagra who experiences aggression and homicidal tendencies
== Spatial position in membrane == Orientations and penetration depths of many amphitropic proteins and peptides in membranes are studied using site-directed spin labeling, chemical labeling, measurement of membrane binding affinities of protein mutants, fluorescence spectroscopy, solution or solid-state NMR spectroscopy, ATR FTIR spectroscopy, X-ray or neutron diffraction, and computational methods. Two distinct membrane-association modes of proteins have been identified. Typical water-soluble proteins have no exposed nonpolar residues or any other hydrophobic anchors. Therefore, they remain completely in aqueous solution and do not penetrate into the lipid bilayer, which would be energetically costly. Such proteins interact with bilayers only electrostatically, for example, ribonuclease and poly-lysine interact with membranes in this mode. However, typical amphitropic proteins have various hydrophobic anchors that penetrate the interfacial region and reach the hydrocarbon interior of the membrane. Such proteins "deform" the lipid bilayer, decreasing the temperature of lipid fluid-gel transition. The binding is usually a strongly exothermic reaction. Association of amphiphilic α-helices with membranes occurs similarly. Intrinsically unstructured or unfolded peptides with nonpolar residues or lipid anchors can also penetrate the interfacial region of the membrane and reach the hydrocarbon core, especially when such peptides are cationic and interact with negatively charged membranes.
=== Radiotherapy dose enhancer === Considerable interest has been shown in the use of gold and other heavy-atom-containing nanoparticles to enhance the dose delivered to tumors. Since the gold nanoparticles are taken up by the tumors more than the nearby healthy tissue, the dose is selectively enhanced. The biological effectiveness of this type of therapy seems to be due to the local deposition of the radiation dose near the nanoparticles. This mechanism is the same as occurs in heavy ion therapy.
=== EC 1.97.1 Sole sub-subclass for oxidoreductases that do not belong in the other subclasses === EC 1.97.1.1: chlorate reductase EC 1.97.1.2: Now EC 5.4.4.9, pyrogallol hydroxytransferase EC 1.97.1.3: Now EC 1.12.98.4, sulfhydrogenase, since hydrogen is known to be the electron donor EC 1.97.1.4: [formate-C-acetyltransferase]-activating enzyme EC 1.97.1.5: Now EC 1.20.4.1, arsenate reductase (glutaredoxin EC 1.97.1.6: Now EC 1.20.99.1, arsenate reductase (donor) EC 1.97.1.7: Now EC 1.20.4.2, methylarsonate reductase EC 1.97.1.8: Now EC 1.21.99.5, tetrachloroethene reductive dehalogenase EC 1.97.1.9: selenate reductase EC 1.97.1.10: Now EC 1.21.99.4 thyroxine 5′-deiodinase EC 1.97.1.11: Now EC 1.21.99.3 thyroxine 5-deiodinase. EC 1.97.1.12: photosystem I
S: Skin. The skin of the scalp contains numerous hair follicles and sebaceous glands. C: Connective tissue. A dense subcutaneous layer of fat and fibrous tissue that lies beneath the skin, containing the nerves and vessels of the scalp. A: Aponeurosis. The epicranial aponeurosis or galea aponeurotica is a tough layer of dense fibrous tissue which anchors the above layers in place. It runs from the frontalis muscle anteriorly to the occipitalis posteriorly. L: Loose areolar connective tissue. This layer has a gel-like consistency, and allows the more superficial layers of the scalp to shift about in relation to the pericranium. It is constituted of more matrix than fibers. It contains random collagen I bundles, collagen III and is rich in glycosaminoglycans (GAGs). In craniofacial surgery and neurosurgery this layer provides an easy plane of separation between the upper three layers and the pericranium. In scalping the scalp is also torn off through this layer. The layer is sometimes referred to as the "danger zone" because infectious agents can easily spread through it to emissary veins which drain into the cranium. P: Pericranium. This is the periosteum of the skull bones, a membrane that provides nutrition to the bone and the capacity for repair. During surgery it can be lifted from the bone to allow the removal of windows of bone (craniotomy).
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.